Announced
Completed
Synopsis
Merck, an American multinational pharmaceutical company, known as MSD outside the US, completed the acquisition of Themis Bioscience, an international biotech company, from Ventech, Wellington Partners, Omnes Capital, aws Grunderfonds Beteiligungs and Hadean Ventures. Financial terms were not disclosed. Merck will initially focus on speeding up the development of Themis Bioscience’s measles vector-based SARS-CoV-2 vaccine candidate, which is presently in pre-clinical development. Clinical studies of the coronavirus vaccine candidate are targeted to begin later this year.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.